Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

InterbrandHealth

- PMLiVE

Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine

Preliminary laboratory studies show both vaccines neutralise Omicron BA.4 and BA.5

- PMLiVE

Enanta takes legal action against Pfizer over Paxlovid patent infringement

The lawsuit claims the oral COVID-19 antiviral infringes on Enanta’s 11,358,953 patent

- PMLiVE

Pfizer donates $5m in Russian profits to humanitarian causes amid war in Ukraine

The donation will go to eight global and local NGOs to support humanitarian relief and response efforts

- PMLiVE

Novo Nordisk and Echosens collaborate to advance early diagnosis of non-alcoholic steatohepatitis

The companies aim to double diagnostic rates for those with advanced to severe forms of the disease by 2025

- PMLiVE

Pfizer to buy 8.1% stake in Valneva in support of joint Lyme disease programme

VLA15 is the only Lyme disease vaccine candidate currently in clinical development

- PMLiVE

Myovant Sciences and Pfizer publish phase 3 results for endometriosis therapy

Around 200 million women suffer from endometriosis worldwide and it can take between four to eleven years to get a diagnosis

- PMLiVE

MSD and AstraZeneca announce phase 3 results for prostate cancer therapy

The results show that the Lynparza combination therapy significantly improved radiographic progression-free survival

- PMLiVE

FDA grants Pfizer/BioNTech’s COVID-19 vaccine emergency use authorisation for infants

The authorisation is specifically for the children aged six months to four years

- PMLiVE

Pfizer to expand Paxlovid manufacturing in US to meet global demand

The $120m investment will also create more than 250 high-skilled manufacturing jobs

- PMLiVE

Phase 3 trial initiated to evaluate AZ’s Saphnelo in lupus nephritis

The antibody has already been approved to treat systemic lupus erythematosus

- PMLiVE

New Pfizer initiative, ‘An Accord for a Healthier World’, launched to improve global health equity

The company aims to provide support for 1.2 billion people in 45 lower-income countries

- PMLiVE

Results released from new study of AstraZeneca’s COVID-19 antibody

A new study from Oxford University shows that Evusheld is effective in protecting against emerging Omicron variants

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links